Nasdaq-listed Cryoport, a temperature-controlled supply chain solutions company for the life sciences industry, has acquired France-based Cell&Co BioServices for €6.2m (US$6.72m), consisting of an upfront consideration of €3.6m in cash and Cryoport common stock, plus a potential earn-out of €2.5m based on hitting certain financial targets. Cell&Co, a bioservices business providing biorepository, kitting, and logistics…
Home Healthcare Markets International News France: Cryoport accelerates EMEA expansion plans with acquisition of Cell&Co BioServices